Gesa Albers

Gesa Albers

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2020 in Science Immunology
Verified
Journal Article
Closed access
POPatricia P. Ogger
Patricia P. Ogger
GAGesa Albers
Gesa Albers
RHRichard J. Hewitt
Richard J. Hewitt
BOBrendan J. O’sUllivan
Brendan J. O’sUllivan
JPJoseph E. Powell
Joseph E. Powell
ABAdam J. Byrne
Adam J. Byrne
The ACOD1/itaconate axis is a pulmonary regulatory pathway that controls the severity of fibrosis and is a potential therapeutic target in IPF.

15 June 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PMPhilip L. Molyneaux
Philip L. Molyneaux
WFWilliam A. Fahy
William A. Fahy
ABAdam J. Byrne
Adam J. Byrne
RBRebecca Braybrooke
Rebecca Braybrooke
PSPeter Saunders
Peter Saunders
TMToby M. Maher
Toby M. Maher
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal condition for which there are a lack of effective biomarkers to guide therapeutic decision making. Objectives: To determine the relationship between serum concentrations of the cytokeratin fragment CYFRA 21-1 and disease progression and mortality in individuals with IPF enrolled in the Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE) study. Methods: CYFRA 21-1 was identified by immunohistochemistry in samples of human lung obtained at surgery. Concentrations of CYFRA 21-1 were measured using an ELISA-based assay in serum samples collected at baseline, 1 month, and 3 months from 491 individuals with an incident diagnosis of IPF who were enrolled in the PROFILE study and from 100 control subjects at baseline. Study subjects were followed for a minimum of 3 years after their first blood draw. Measurements and Main Results: CYFRA 21-1 localizes to hyperplastic epithelium in IPF lung tissue. Peripheral CYFRA 21-1 concentrations were significantly higher in subjects with IPF than in healthy control subjects in both the discovery (n = 132) (control: 0.96 ± 0.81 ng/ml; vs. IPF: 2.34 ± 2.15 ng/ml; P < 0.0001) and validation (n = 359) (control: 2.21 ± 1.54 ng/ml; and IPF: 4.13 ± 2.77 ng/ml; P < 0.0001) cohorts. Baseline concentrations of CYFRA 21-1 were able to distinguish individuals at risk of 12-month disease progression (C-statistic, 0.70; 95% confidence interval, 0.61–0.79; P < 0.0001) and were predictive of overall mortality (hazard ratio, 1.12 [95% confidence interval, 1.06–1.19] per 1 ng/ml increase in CYFRA 21-1; P = 0.0001). Furthermore, 3-month change in concentrations of CYFRA 21-1 separately predicted 12-month and overall survival in both the discovery and validation cohorts. Conclusions: CYFRA 21-1, a marker of epithelial damage and turnover, has the potential to be an important prognostic and therapeutic biomarker in individuals with IPF.

15 October 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PMPeter McErlean
Peter McErlean
CBChristopher G. Bell
Christopher G. Bell
RHRichard J. Hewitt
Richard J. Hewitt
ZBZabreen Busharat
Zabreen Busharat
POPatricia P. Ogger
Patricia P. Ogger
ABAdam J. Byrne
Adam J. Byrne
Rationale: Airway macrophages (AMs) are key regulators of the lung environment and are implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a fatal respiratory disease with no cure. However, knowledge about the epigenetics of AMs in IPF is limited. Objectives: To assess the role of epigenetic regulation of AMs during lung fibrosis. Methods: We undertook DNA methylation (DNAm) profiling by using Illumina EPIC (850k) arrays in sorted AMs from healthy donors (n = 14) and donors with IPF (n = 30). Cell-type deconvolution was performed by using reference myeloid-cell DNA methylomes. Measurements and Main Results: Our analysis revealed that epigenetic heterogeneity was a key characteristic of IPF AMs. DNAm “clock” analysis indicated that epigenetic alterations in IPF AMs were not associated with accelerated aging. In differential DNAm analysis, we identified numerous differentially methylated positions (n = 11) and differentially methylated regions (n = 49) between healthy and IPF AMs, respectively. Differentially methylated positions and differentially methylated regions encompassed genes involved in lipid (LPCAT1 [lysophosphatidylcholine acyltransferase 1]) and glucose (PFKFB3 [6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3]) metabolism, and importantly, the DNAm status was associated with disease severity in IPF. Conclusions: Collectively, our data identify that changes in the epigenome are associated with the development and function of AMs in the IPF lung.

17 January 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
WAWael Awad
Wael Awad
JMJemma R. Mayall
Jemma R. Mayall
WXWeijun Xu
Weijun Xu
Matt JohansenMatt Johansen
Matt Johansen
TPTimothy Patton
Timothy Patton
JRJamie Rossjohn
Jamie Rossjohn
Tobacco smoking is prevalent across the world and causes numerous diseases. Cigarette smoke (CS) compromises immunity, yet little is known of the components of CS that impact T cell function. MR1 is a ubiquitous molecule that presents bacterial metabolites to MAIT cells, which are highly abundant in the lungs. Using in silico, cellular, and biochemical approaches, we identified components of CS that bind MR1 and impact MR1 cell surface expression. Compounds, including nicotinaldehyde, phenylpropanoid, and benzaldehyde-related scaffolds, bound within the A′ pocket of MR1. CS inhibited MAIT cell activation, ex vivo, via TCR-dependent and TCR-independent mechanisms. Chronic CS exposure altered MAIT cell phenotype and function and attenuated MAIT cell responses to influenza A virus infection in vivo. MR1-deficient mice were partially protected from the development of chronic obstructive pulmonary disease (COPD) features that were associated with CS exposure. Thus, CS can impair MAIT cell function by diverse mechanisms, and potentially contribute to infection susceptibility and disease exacerbations.

28 January 2021 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
GAGesa Albers
Gesa Albers
JIJ Iwasaki
J Iwasaki
PMP McErlean
P McErlean
POP P Ogger
P P Ogger
PGP Ghai
P Ghai
ABA J Byrne
A J Byrne
Summary: Interferon regulatory factor 5 (IRF5) is a master regulator of macrophage phenotype and a key transcription factor involved in expression of proinflammatory cytokine responses to microbial and viral infection. Here, we show that IRF5 controls cellular and metabolic responses. By integrating ChIP sequencing (ChIP-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC)-seq data sets, we found that IRF5 directly regulates metabolic genes such as hexokinase-2 (Hk2). The interaction of IRF5 and metabolic genes had a functional consequence, as Irf5−/− airway macrophages but not bone marrow-derived macrophages (BMDMs) were characterized by a quiescent metabolic phenotype at baseline and had reduced ability to utilize oxidative phosphorylation after Toll-like receptor (TLR)-3 activation, in comparison to controls, ex vivo. In a murine model of influenza infection, IRF5 deficiency had no effect on viral load in comparison to wild-type controls but controlled metabolic responses to viral infection, as IRF5 deficiency led to reduced expression of Sirt6 and Hk2. Together, our data indicate that IRF5 is a key component of AM metabolic responses following influenza infection and TLR-3 activation.

17 July 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
JOJustin M. Oldham
Justin M. Oldham
KJKirk W. Johnson
Kirk W. Johnson
GAGesa Albers
Gesa Albers
ECEmily Calamita
Emily Calamita
JMJordina Mah
Jordina Mah
ABAdam J. Byrne
Adam J. Byrne
Idiopathic pulmonary fibrosis (IPF) is a chronic debilitating lung disease, characterised by progressive deposition of excessive extracellular matrix in the lung parenchyma [1]. Though rare, IPF has a median untreated survival of 3 years from diagnosis, making it more deadly than many cancers [2, 3]. Two antifibrotic therapies, pirfenidone and nintedanib, have been shown to effectively slow IPF progression, but neither stop or reverse fibrogenesis [3]. Thus, there is an urgent unmet clinical need to develop more effective treatments for IPF and identify biomarkers.